EXECUTIVE ENGAGEMENTS
POOL
INTERACTIONS
PARTICIPANTS
VALIDATIONS
COMPANIES
* Login for a full stack data experience
DATE
JAN 2023
TABLES
90
PAGES
356
EDITION
18
PRICE
USD 5450
CODE
MCP-6847
*Engagement stats are ongoing and dynamic
HIGHLIGHTS & REPORT INDEX
What`s New for 2023?
»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
»Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
»Online interactive peer-to-peer collaborative bespoke updates
»Access to our digital archives and MarketGlass Research Platform
»Complimentary updates for one year
Looking Ahead to 2023
The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.
Global Acute Myeloid Leukemia (AML) Therapeutics Market to Reach $1.6 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Acute Myeloid Leukemia (AML) Therapeutics estimated at US$587.6 Million in the year 2022, is projected to reach a revised size of US$1.6 Billion by 2030, growing at a CAGR of 13.4% over the analysis period 2022-2030. Cytarabine, one of the segments analyzed in the report, is projected to record a 15.6% CAGR and reach US$571.6 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Anthracycline Drugs segment is readjusted to a revised 14.5% CAGR for the next 8-year period.
The U.S. Market is Estimated at $217.3 Million, While China is Forecast to Grow at 15.4% CAGR
The Acute Myeloid Leukemia (AML) Therapeutics market in the U.S. is estimated at US$217.3 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$151 Million by the year 2030 trailing a CAGR of 15.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12% and 12.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12.9% CAGR.
SELECT PLAYERS
Amgen, Inc.; Astellas Pharma, Inc.; AbbVie, Inc.; A. Menarini Industrie Farmaceutiche Riunite Srl; Actinium Pharmaceuticals, Inc.; Aptose Biosciences, Inc.; Aprea Therapeutics; Astex Pharmaceuticals, Inc.; AB Science SA; Aptevo Therapeutics; Ascentage Pharma; arGEN-X; Accent Therapeutics; Arcellx; Amphivena Therapeutics
SEGMENTS
» Chemotherapy Type (Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites, Other Chemotherapy Types)
GEOGRAPHIES
» World » USA » Canada » Japan » China » Europe » France » Germany » Italy » UK » Spain » Russia » Rest of Europe » Asia-Pacific » Australia » India » South Korea » Rest of Asia-Pacific » Latin America » Middle East » Africa
TABLE OF CONTENTS
I. METHODOLOGY |
II. EXECUTIVE SUMMARY |
1. MARKET OVERVIEW |
COVID-19 IMPACT AND THE LOOMING RECESSION |
COVID-19’s Impact on Cancer Patients |
Making the Cancer Patient Survive the Lethal Covid-19 Wave |
Post-Covid-19 Complications to Affect Future Cancer Treatment |
The Evolving Model of Care - Virtual/ Telemedicine Consultations |
The Evolving Model of Care - Extending Care through Innovative Means |
Pandemic Causes Delays in Procedures and Treatment |
In-Office Cancer Patient Visits Decline amidst Pandemic |
Vaccine Availability Comforts Cancer Patients |
COVID-19 IMPACT ON ACUTE MYELOID LEUKEMIA THERAPEUTICS |
Pandemic Caused Delays Impact AML Patients |
Pandemic Related Issues Affect Oncology Research |
Competition |
Competitive Market Presence - Strong/Active/Niche/Trivial for 67 Players Worldwide in 2022 (E) |
Acute Myeloid Leukemia (AML) Therapeutics – Global Key Competitors Percentage Market Share in 2022 (E) |
LEUKEMIA – A DISEASE OF THE BONE MARROW |
A Prelude to Acute Myeloid Leukemia (AML) |
Acute Myeloid Leukemia: Epidemiology |
Acute Myeloid Leukemia (AML) Types |
Etiology of AML |
AML Symptoms |
GLOBAL MARKET OUTLOOK AND PROSPECTS |
Acute Myeloid Leukemia (AML) Therapeutics Market Primed for Massive Growth with Rising Patient Count & Promising Research Efforts |
Drug Development Efforts Set Pace for Global Market |
New Therapies Introduced in the Landscape |
RECENT LAUNCHES IN THE AML MARKET |
North America Maintains Leadership Position in Global Market |
Chemotherapy: The Standard Mode of Treatment for AML Over the Years |
Emerging Drug Therapies/Targeted Therapies for Acute Myeloid Leukemia to Drive the Market |
FLT3 Inhibitors & Cytarabine: Bright Segments of Acute Myeloid Leukemia Therapeutics Market |
Global FLT3 Inhibitors Market: Annual Sales in US$ Million for Years 2020 through 2027 |
EXISTING & POTENTIAL TREATMENT/THERAPEUTIC TARGETS FOR ACUTE MYELOID LEUKEMIA |
Chemotherapy |
AML Treatment |
Stem Cell Transplant for Acute Myeloid Leukemia (AML) |
Targeted Therapies Drive the Future of AML Market |
ISOCITRATE DEHYDROGENASES (IDH) |
BCL-2 Inhibitor |
FLT3 |
Hedgehog (Hh) |
Immunotherapy-Oriented Treatments |
Neurotransmitter Receptors |
Epigenetic Modulators |
Organelle-Directed Strategies |
New Formulations Using Existing Options |
Antibody–Drug Conjugate Therapy for Acute Leukemia |
Targeted Therapies Market for AML by Product Class: Market Size Estimates in USD Million for 2020 |
Targeted Therapies Market for AML (2020) by Leading Drugs: Market Share of Revenues |
RECENT MARKET ACTIVITY |
2. FOCUS ON SELECT PLAYERS |
3. MARKET TRENDS & DRIVERS |
High Incidence and Prevalence Drive Market Growth |
Ballooning Elderly Population: The Vital Growth Driver for AML Therapeutics |
EXHIBIT 12: Expanding Elderly Population Worldwide: Breakdown of Number of People Aged 65+ Years in Million by Geographic Region for the Years 2019 and 2030 |
Life Expectancy for Select Countries in Number of Years: 2019 |
Advancements in Pharmacology & Molecular Biology to Promote AML Drug Development |
Recent Drug Approvals |
Rising Investments in AML Therapeutics R&D Augurs Well |
Changing Face of Combination Therapies Improve Outcomes for treated Secondary AML |
University of Texas’ Combination Therapy Study Shines Light at the end of Tunnel for Acute Myeloid Leukemia |
Need for Better Treatments Entrenches Proteomics at Center of Acute Myeloid Leukemia Therapeutics R&D |
Antibody-Oriented Protein Microarrays |
AML - A Medical Challenge with High Relapse Rate |
Therapeutic Landscape for Refractory/Relapsed Acute Myeloid Leukemia |
Advances Related to FLT3 Inhibitors |
Novel Combination Therapies for Relapsed or Refractory AML |
Novel Therapies for Treatment of Pediatric Relapsed AML |
Immunotherapy Research for AML |
Monoclonal Antibody (Mylotarg) – A Promising Drug |
Chemotherapy Complications to Hinder the AML Market Growth |
4. GLOBAL MARKET PERSPECTIVE |
World Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Cytarabine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Cytarabine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Cytarabine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Anthracycline Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Anthracycline Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Anthracycline Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Tyrosine Kinase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Tyrosine Kinase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Alkylating Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Alkylating Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Hormonal Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Hormonal Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Anti-Metabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Anti-Metabolites by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Anti-Metabolites by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Recent Past, Current & Future Analysis for Other Chemotherapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
World Historic Review for Other Chemotherapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
World 16-Year Perspective for Other Chemotherapy Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030 |
World Acute Myeloid Leukemia (AML) Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030 |
III. MARKET ANALYSIS |
UNITED STATES |
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E) |
USA Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
USA Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
USA 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
CANADA |
Canada Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Canada Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Canada 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
JAPAN |
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E) |
Japan Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Japan Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Japan 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
CHINA |
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E) |
China Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
China Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
China 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
EUROPE |
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E) |
Europe Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030 |
Europe Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Europe 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
FRANCE |
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E) |
France Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
France Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
France 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
GERMANY |
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E) |
Germany Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Germany Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Germany 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
ITALY |
Italy Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Italy Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Italy 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
UNITED KINGDOM |
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E) |
UK Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
UK Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
UK 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
SPAIN |
Spain Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Spain Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Spain 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
RUSSIA |
Russia Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Russia Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Russia 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
REST OF EUROPE |
Rest of Europe Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Europe Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Rest of Europe 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
ASIA-PACIFIC |
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E) |
Asia-Pacific Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR |
Asia-Pacific Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Asia-Pacific 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030 |
Asia-Pacific Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Asia-Pacific Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Asia-Pacific 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
AUSTRALIA |
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E) |
Australia Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Australia Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Australia 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
INDIA |
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E) |
India Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
India Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
India 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
SOUTH KOREA |
South Korea Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
South Korea Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
South Korea 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
REST OF ASIA-PACIFIC |
Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Rest of Asia-Pacific Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Rest of Asia-Pacific 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
LATIN AMERICA |
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E) |
Latin America Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Latin America Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Latin America 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
MIDDLE EAST |
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E) |
Middle East Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Middle East Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Middle East 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
AFRICA |
Acute Myeloid Leukemia (AML) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E) |
Africa Recent Past, Current & Future Analysis for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR |
Africa Historic Review for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR |
Africa 16-Year Perspective for Acute Myeloid Leukemia (AML) Therapeutics by Chemotherapy Type - Percentage Breakdown of Value Sales for Cytarabine, Anthracycline Drugs, Tyrosine Kinase Inhibitors, Alkylating Agents, Hormonal Therapy, Anti-Metabolites and Other Chemotherapy Types for the Years 2014, 2023 & 2030 |
IV. COMPETITION |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com